Central to its near-term growth plan is the performance of Austedo (deutetrabenazine), approved for Huntington’s disease and tardive dyskinesia, which Teva predicts will bring in $2.5 billion in ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Also underway, on the flipside, was the decision to ramp up investment in one of Teva’s stable of innovative products, Austedo (deutetrabenazine), a treatment for tardive dyskinesia and chorea ...

Revenue in Teva’s U.S. business grew 4% to $8.03 billion driven largely by AUSTEDO and biosimilars but that growth hasn’t been enough to offset other pressures. Gross margin dropped from 55.7% ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong performance across its innovative, generics, and API businesses. AUSTEDO sales grew by 34%, reaching $1.7 ...

"I don't think having Teva part of that and having Austedo, a rare disease (treatment), part of that is necessarily the intent of the IRA," he said. Speaking at the news conference on Monday ...

TEVA) made notable progress, contributing to both growth and financial stability. Key products like AUSTEDO, UZEDY, and AJOVY led revenue growth, with AUSTEDO seeing a 34% sales increase ...